SCHEMBL17211650

SCHEMBL17211650

COc1c(/C=C/C(=O)OC(C)(C)C)cc(N(C)S(=O)(=O)c2cccs2)c2c1OCO2

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CNKSR1 Q969H4 10/20 0.46
AKT1 P31749 1/20 0.44
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
LMNA P02545 1/20 0.34
TNFRSF1A P19438 1/20 0.34
MAPT P10636 1/20 0.34
PTGER1 P34995 1/20 0.33
PTGER4 P35408 1/20 0.33
PTGER3 P43115 1/20 0.33
PTGER2 P43116 1/20 0.33
NR1H3 Q13133 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17211661 0.82 CNKSR1 (0.63) CNKSR1AKT1MAPTPTGER1PTGER4
SCHEMBL15811504 0.72 CNKSR1 (0.81) CNKSR1AKT1MAPTPTGER1PTGER4
SCHEMBL17211669 0.71 CNKSR1 (0.78) CNKSR1AKT1MAPTALDH1A1SMN1; SMN2
SCHEMBL17200780 0.70 CNKSR1 (0.76) CNKSR1AKT1MAPTPTGER1PTGER4
SCHEMBL15811477 0.70 CNKSR1 (0.76) CNKSR1AKT1MAPTPTGER1PTGER4
SCHEMBL20798600 0.70 CNKSR1 (0.76) CNKSR1AKT1MAPTPTGER1PTGER4
SCHEMBL17211718 0.69 CNKSR1 (0.64) CNKSR1AKT1PTGER1PTGER4PTGER3
SCHEMBL17211657 0.68 CNKSR1 (0.60) CNKSR1AKT1PTGER1PTGER4PTGER3
SCHEMBL18160902 0.67 CNKSR1 (0.57) CNKSR1AKT1RAB9ANPC1L3MBTL1
SCHEMBL18160885 0.67 CNKSR1 (0.75) CNKSR1AKT1MAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340532-B2 Methods and compositions for inhibiting CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2016-05-17 US disclosed
US-9340532-B2 Methods and compositions for inhibiting CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2016-05-17 US disclosed
US-20150307482-A1 METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2015-10-29 US disclosed
US-20150307482-A1 METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2015-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307482-A1 METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 CNKSR1, CAMKK1, CAMKK2 CNKSR1 1/4885AKT1 936/4885RAB9A 3396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.